ReviewJournal of inflammation research2025
Targeting Eosinophils in Asthmatic Inflammation: Benefits and Drawbacks.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- pIgR Stem Zone-Targeted Nanobodies as Apical-to-Basolateral Carriers for Inhaled Biologic Delivery Across Mucosal Barriers.Antibodies (Basel, Switzerland) · 2026Article
- Nasal Cytology as a Local Biomarker of Airway Inflammation: A Paradigm Shift in Precision Medicine.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- JESREC score, metabolic factors, and pulmonary dysfunction: analysis among adult patients with chronic rhinosinusitis.Frontiers in medicine · 2026Article
- Immunoregulatory mechanisms in parasitic eosinophilic lung disease: the role of IgE immune complexes and NLRC4 inflammasome.Frontiers in immunology · 2026Review
- Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is associated with eosinophilic airway inflammation which contributes to poor asthma outcomes in a subset of severe asthmatics. This review traces the scientific rationale as well as the clinical development of novel therapeutics to target either IL-5 or the IL-5α receptor to deplete eosinophils from the airway to improve asthma outcomes in severe asthma with eosinophilic airway inflammation. The importance of IL-5 to eosinophil growth, survival, and function was initially identified in mice, and has been confirmed in studies of human eosinophils. As both IL-5 and the IL-5α receptor were identified as therapeutic targets to deplete eosinophils in the airway in asthmatics, humanized IgG antibodies were developed to target either IL-5 or the IL-5α receptor in eosinophilic asthma. The current availability of three biologics that deplete eosinophils (mepolizumab, reslizumab, and benralizumab) has provided a novel therapeutic approach to treat severe asthma with eosinophilic inflammation not controlled by inhaled corticosteroids in combination with long acting bronchodilators. Two of these eosinophil targeted biologics (mepolizumab, reslizumab) target IL-5 an eosinophil growth factor, while the third eosinophil targeted biologic (benralizumab) targets the IL-5α receptor expressed by eosinophils. Each of these eosinophil targeted therapies significantly deplete eosinophils in the blood, sputum, and airway and are associated with a significant approximately 50% reduction in asthma exacerbations in most studies without significant side effects. In addition, selected studies have shown that eosinophil targeted biologics improve asthma symptom quality of life scores and lung function. At present, there are no direct head to head comparison studies to determine whether any of the three eosinophil targeted biologics has a better asthma outcome profile/safety profile. The development of eosinophil targeted biologics has been a significant advance in the treatment of severe asthma with eosinophilic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.